반응식
[N:1]1([C:20]([O:22][C:23]([CH3:26])([CH3:25])[CH3:24])=[O:21])[CH2:6][CH2:5][C:4]2([C:14]3[C:9](=[CH:10][CH:11]=[C:12]([C:15]([O:17][CH2:18][CH3:19])=[O:16])[CH:13]=3)[N:8]=[CH:7]2)[CH2:3][CH2:2]1.C(OC(C)(C)C)=O>>[N:1]1([C:20]([O:22][C:23]([CH3:24])([CH3:26])[CH3:25])=[O:21])[CH2:6][CH2:5][C:4]2([C:14]3[C:9](=[CH:10][CH:11]=[C:12]([C:15]([O:17][CH2:18][CH3:19])=[O:16])[CH:13]=3)[NH:8][CH2:7]2)[CH2:3][CH2:2]1참가 물질
3
실험 절차
1′-tert-butyl 5-ethyl spiro[indoline-3,4′-piperidine]-1′,5-dicarboxylate was prepared by the procedures described in Example 1, Step 2, substituting tert-butyl 5-chlorospiro[indole-3,4′-piperidine]-1′-carboxylate with 1′-tert-butyl 5-ethyl spiro[indole-3,4′-piperidine]-1′,5-dicarboxylate. LCMS (APCI+) m/z 261.3 [M+H−Boc]+; Rt=3.76 min.
출처 및 근거
- ORD 기록
- ord-76d5be6ca32043b4b8f62ad7144f8cff
- 출처 데이터셋
- uspto-grants-2016_05
- 특허 번호
- US09346805B2
연결된 노트
불러오는 중…